Figure 1. 2.5 × 10⁵ TC.1 cells were subcutaneously implanted in the flanks of five mice per group. One group of mice was treated with Lm-LLO-E7, one group of mice was treated with a control vaccine (Lm-LLO-OVA) and the third group was treated with PBS when tumors reached 7–8 mm. Mice were treated with a second dose of Lm-LLO-E7, Lm-LLO-OVA or PBS 7 d following the initial dose. Mice were removed from the study 5 d following the second treatment as tumors of Lm-LLO-E7 treated mice were undergoing regression. Mean+/−SEM for each group are shown (A). Tumor lysates were equilibrated based on total protein content. 50 µg of total protein were analyzed, in duplicate, for the presence of IL-17A via ELISA. Values represent pg of IL-17A per mg of total tumor protein. Mean+/−SEM for each group (n = 3) are shown (B).